Cargando…

Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014

BACKGROUND: The most-used protease-inhibitor in children is Lopinavir-ritonavir (LPV/r), which provides durable suppression of viral load and increases CD4+T-counts. This study describes the virological outcome of the HIV-1-infected paediatric population exposed to LPV/r during 15 years in Spain. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rojas Sánchez, Patricia, Prieto, Luis, Jiménez De Ory, Santiago, Fernández Cooke, Elisa, Navarro, Maria Luisa, Ramos, José Tomas, Holguín, África
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369685/ https://www.ncbi.nlm.nih.gov/pubmed/28350802 http://dx.doi.org/10.1371/journal.pone.0173168

Ejemplares similares

Pregnancy outcomes in perinatally HIV-infected young women in Madrid, Spain: 2000-2015
por: Prieto, Luis M., et al.
Publicado: (2017)

Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
por: Beltrán-Pavez, Carolina, et al.
Publicado: (2020)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19
por: Echarte-Morales, Julio, et al.
Publicado: (2021)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Lopinavir/ritonavir/sotalol: Various toxicities: 9 case reports
Publicado: (2021)

Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
Publicado: (2022)

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
por: Ader, Florence, et al.
Publicado: (2021)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain
por: Domínguez-Rodríguez, Sara, et al.
Publicado: (2020)

Determinants of Highly Active Antiretroviral Therapy Duration in HIV-1-Infected Children and Adolescents in Madrid, Spain, from 1996 to 2012
por: Palladino, Claudia, et al.
Publicado: (2014)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
por: Martinez, Beatriz Larru, et al.
Publicado: (2010)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
por: Greffrath, Wilhelm P., et al.
Publicado: (2018)

A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir
por: Joumaa, H., et al.
Publicado: (2020)

Hydroxychloroquine/lopinavir/ritonavir: Various side effects: 7 case reports
Publicado: (2020)

Lopinavir/ritonavir: Hyperlipidaemia following off-label use: case report
Publicado: (2020)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Lopinavir/ritonavir: Bradyarrhythmia following an off-label use : case report
Publicado: (2020)

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
por: Cao, Bin, et al.
Publicado: (2020)

Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
por: Mas Serrano, Miguel, et al.
Publicado: (2020)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
por: Owa, Adewale Bayode, et al.
Publicado: (2020)

Lopinavir/ritonavir/prednisone: Knee osteonecrosis and its worsening: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1p8ihei8a4f33qbindp7tj1k6n